Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
grade F 17.88 -1.65% -0.30
NXTC closed down 1.65 percent on Friday, July 10, 2020, on 1.81 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical NXTC trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -1.65%
Wide Bands Range Expansion -1.65%
Lower Bollinger Band Touch Weakness -1.65%
Oversold Stochastic Weakness -1.65%
Lower Bollinger Band Walk Weakness -3.97%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Medicine Biopharmaceutical Health Cancer Clinical Medicine Immunotherapy Cancer Treatments Virotherapy Tumor Non Small Cell Lung Cancer Ovarian Cancer Oncolytics Biotech Metastasis Treatment Of Ovarian Cancer Halozyme Immune Related Diseases Yale University

Is NXTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 109.0
52 Week Low 16.04
Average Volume 391,296
200-Day Moving Average 38.54
50-Day Moving Average 28.23
20-Day Moving Average 22.22
10-Day Moving Average 20.05
Average True Range 2.04
ADX 33.86
+DI 8.72
-DI 29.70
Chandelier Exit (Long, 3 ATRs ) 21.06
Chandelier Exit (Short, 3 ATRs ) 23.67
Upper Bollinger Band 27.13
Lower Bollinger Band 17.31
Percent B (%b) 0.06
BandWidth 44.15
MACD Line -2.79
MACD Signal Line -2.60
MACD Histogram -0.1827
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.23
Resistance 3 (R3) 19.27 18.86 19.01
Resistance 2 (R2) 18.86 18.52 18.84 18.93
Resistance 1 (R1) 18.37 18.30 18.17 18.33 18.85
Pivot Point 17.96 17.96 17.86 17.94 17.96
Support 1 (S1) 17.47 17.62 17.27 17.43 16.91
Support 2 (S2) 17.06 17.40 17.04 16.83
Support 3 (S3) 16.57 17.06 16.76
Support 4 (S4) 16.53